FRANCE – Kiro, a Paris, France-based digital medicine company, raised €13.8M in Series A funding.
The round, which brought the total amount to €17M, was led by Sofinnova Partners, with participation from previous investors Bpifrance, through its Fonds Ambition Amorçage Angels (F3A), Kurma Partners and Propulia Capital.The company intends to use the funds to further develop its technology and platform, to reinforce its position in France, expand commercial operations in Europe, and prepare entry into the US market.Founded in 2019 and led by CEO Alexandre Guenoun, Kiro provides an AI-powered digital health platform for clinical biology in Europe. It is committed to developing new approaches to medical biology using medical-grade artificial intelligence and cloud technology and leverages laboratory results to bring better outcomes for patients. Developed in partnership with laboratories, hospitals and physicians, its solutions offer personalized results for patients and caregivers while helping healthcare providers follow and treat their patients with real-time clinical decision support tools (prevention, diagnosis, etc.). Medically validated, the system can help interpret data from a broad range of lab tests and generate a report within seconds, enabling efficient patient care and empowering clinicians worldwide to deliver their expertise.31/03/2023
